Cancer-associated fibroblasts in cholangiocarcinoma.

Javier Vaquero, Lynda Aoudjehane, Laura Fouassier

Journal: Current opinion in gastroenterology 2020;36(2):63-69

PMID: 31934895

Abstract

PURPOSE OF REVIEW

To give a state-of-art knowledge regarding cancer-associated fibroblasts (CAF) in cholangiocarcinoma (CCA) based both on direct evidence and studies on other desmoplastic cancers. High contingency of CAF characterizes CCA, a tumor with a biliary epithelial phenotype that can emerge anywhere in the biliary tree. Current treatments are very limited, the surgical resection being the only effective treatment but restricted to a minority of patients, whereas the remaining patients undergo palliative chemotherapy regimens. In cancer, CAF shape the tumor microenvironment, drive cancer growth and progression, and contribute to drug resistance. All these functions are accomplished through an interplay network between CAF and surrounding cells including tumor and other stromal cells, i.e. immune and endothelial cells.

RECENT FINDINGS

Several studies have pointed out the existence of CAF sub-populations carrying out several and opposite functions, cancer-promoting or cancer-restraining as shown in pancreatic cancer, another prototypic desmoplastic tumor in which heterogeneity of CAF is well demonstrated.

SUMMARY

New CAF functions are now emerging in pancreatic and breast cancers like the modulation of immune responses or tumor metabolism, opening new area for treatments.

Address: Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine, CRSA.; LPP, CNRS, Ecole Polytech., University Paris-Sud, Observatoire de Paris, University Paris-Saclay, Sorbonne Université, PSL Research University.; Sorbonne Université, Inserm, Institute of Cardiometabolism and Nutrition, ICAN, Paris, France.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.